Reproxalap is a small molecule commercialized by Aldeyra Therapeutics, with a leading Phase III program in Allergic Conjunctivitis. According to Globaldata, it is involved in 25 clinical trials, of which 24 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Reproxalap’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Reproxalap is expected to reach an annual total of $250 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Reproxalap Overview
Reproxalap (ADX-102) is under development for allergic conjunctivitis, dry eye syndrome and coronavirus disease 2019 (COVID-19). It is administered through oral, dermal and ophthalmic routes. It is developed based on pro-inflammatory reactive aldehyde species (RASP) scavenger platform. It is also under development for oral formulation indications including amino acid metabolism disorder including succinic semialdehyde dehydrogenase deficiency (SSADH) (oral formulation).
The drug candidate was also under development for the treatment of sjogren-larsson syndrome, discoid lupus erythematosus, congenital ichthyosis in subjects with dermatitis including contact dermatitis and allergic dermatitis, ocular inflammation including ocular rosacea with meibomian gland dysfunction, radiation-induced oral mucositis and acute non-infectious anterior uveitis.
Aldeyra Therapeutics Overview
Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, ADX-2191, RASP-Inhibitor Discovery Platform, ADX-629, ADX-246 and ADX-248. Reproxalap is used to treat dry eye disease, allergic conjunctivitis and proliferative vitreoretinopathy. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. It develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Reproxalap’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
